Lowering plasma free fatty acids with acipimox mimics the antidiabetic effects of the β3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats

Metabolism: Clinical and Experimental

Volumn 50, Issue 8, 2001, Pages 945-951

  Blachére, Jean Christophe ^a   Pérusse, Fleurette ^a   Bukowiecki, Ludwik J ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ACIMOX; ACIPIMOX; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; DEOXYGLUCOSE; FATTY ACID; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CLAMP; CONTROLLED STUDY; DIABETIC OBESITY; DIAPHRAGM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEART; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; LIPOLYSIS; LONG TERM CARE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; RAT STRAIN; SKELETAL MUSCLE; THERMOGENESIS; TISSUE DISTRIBUTION; WHITE ADIPOSE TISSUE;

EID: 0034863928     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.24868     Document Type: Article

References (36)

1. Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats
2. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus
3. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships
4. Post-GLUT-2 defects in beta-cells of non-insulin-dependent diabetic obese rats
5. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat
6. Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose- stimulated insulin secretion
7. Major thermogenic defect associated with insulin resistance in brown adipose tissue of obese diabetic SHR/N-cp rats
8. Specific decrease of mitochondrial thermogenic capacity in brown adipose tissue of obese SHR/N-cp rats
9. Appearance of brown adipocytes in white adipose tissue during CL 316, 243-induced reversal of obesity and diabetes in Zucker fa/fa rats
10. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
11. Fuel selection in human skeletal muscle in insulin resistance: A reexamination
12. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance
13. Mechanisms of the beneficial effects of the selective β3-agonist CL 316 243 on obesity, diabetes and energy expenditure
14. Inhibition of lipolysis by nicotinic acid and by acipimox
15. 1 I - Mechanism of action
16. 1 II - Antilipolytic and blood lipid lowering activity
17. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent
18. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocyte
19. Chronic norepinephrine infusion stimulates glucose uptake in white and brown adipose tissues
20. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats
21. Mechanisms of the anti-diabetic effects of acipimox in type I and type II diabetic rats
22. Stimulatory effects of cold exposure and cold acclimation on glucose uptake in rat peripheral tissues
23. Cold exposure reverses the diabetogenic effect of high-fat feeding
24. Morphometric-stereologic analysis of brown adipocytes in lean and obese SHR/N-cp rats
25. Effect of CL-316, 243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats
26. Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta(3)-adrenoceptor agonist
27. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
28. Leptin receptor missense mutation in the fatty Zucker rat
29. Substitution at codon 269 (glutamine→proline) of the leptin receptor (OB-R) cDNA is the only mutation found in the Zucker fatty (fa/fa) rat
30. Neural control of brown adipose tissue thermogenesis, hypertrophy, and atrophy
31. Increase in insulin action and fat oxidation after treatment with CL 316, 243, a highly selective beta3-adrenoceptor agonist in humans
32. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes - An update
33. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus
34. Metabolic effects of suppression of nonsterified fatty acid levels with acipimox in obese NIDDM subjects
35. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
36. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients